Benzinga | May 18, 2021 07:02AM EDT

Piper Sandler Initiates Coverage On Rain Therapeutics with Overweight Rating, Announces Price Target of $25

Piper Sandler analyst Joseph Catanzaro initiates coverage on Rain Therapeutics (NASDAQ:RAIN) with a Overweight rating and announces Price Target of $25.